Aerie Pharmaceuticals (NASDAQ:AERI) was downgraded by equities research analysts at BidaskClub from a “hold” rating to a “sell” rating in a research report issued on Saturday.
AERI has been the topic of a number of other research reports. Mizuho reaffirmed a “buy” rating and set a $87.00 target price on shares of Aerie Pharmaceuticals in a research note on Thursday, November 9th. HC Wainwright assumed coverage on shares of Aerie Pharmaceuticals in a research note on Friday, February 16th. They set a “buy” rating and a $78.00 target price on the stock. Canaccord Genuity lifted their target price on shares of Aerie Pharmaceuticals from $73.00 to $86.00 and gave the company a “buy” rating in a research note on Thursday, January 25th. Seaport Global Securities assumed coverage on shares of Aerie Pharmaceuticals in a research note on Friday, January 26th. They set a “buy” rating and a $78.00 target price on the stock. Finally, Zacks Investment Research lowered shares of Aerie Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, February 2nd. One investment analyst has rated the stock with a sell rating, three have given a hold rating and twelve have issued a buy rating to the company’s stock. Aerie Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $74.21.
Shares of Aerie Pharmaceuticals (NASDAQ AERI) opened at $53.85 on Friday. The firm has a market cap of $2,030.00, a PE ratio of -16.07 and a beta of 0.87. The company has a debt-to-equity ratio of 0.78, a quick ratio of 15.24 and a current ratio of 15.24. Aerie Pharmaceuticals has a 52 week low of $38.14 and a 52 week high of $66.60.
Hedge funds and other institutional investors have recently modified their holdings of the stock. QS Investors LLC purchased a new position in Aerie Pharmaceuticals during the 4th quarter valued at about $125,000. Ameritas Investment Partners Inc. lifted its position in Aerie Pharmaceuticals by 11.5% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,665 shares of the company’s stock valued at $140,000 after acquiring an additional 275 shares during the period. Public Employees Retirement Association of Colorado purchased a new position in Aerie Pharmaceuticals during the 4th quarter valued at about $176,000. Quantbot Technologies LP lifted its position in Aerie Pharmaceuticals by 792.5% during the 3rd quarter. Quantbot Technologies LP now owns 2,981 shares of the company’s stock valued at $144,000 after acquiring an additional 2,647 shares during the period. Finally, Great West Life Assurance Co. Can lifted its position in Aerie Pharmaceuticals by 65.0% during the 3rd quarter. Great West Life Assurance Co. Can now owns 4,160 shares of the company’s stock valued at $204,000 after acquiring an additional 1,639 shares during the period. 99.02% of the stock is owned by institutional investors.
ILLEGAL ACTIVITY NOTICE: “BidaskClub Lowers Aerie Pharmaceuticals (AERI) to Sell” was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this news story on another publication, it was stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this news story can be read at https://www.dispatchtribunal.com/2018/02/24/bidaskclub-lowers-aerie-pharmaceuticals-aeri-to-sell.html.
About Aerie Pharmaceuticals
Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).
Receive News & Ratings for Aerie Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.